Kerrisdale Advisers’s Achillion Pharmaceuticals ACHN Stock Holding History

Kerrisdale Advisers’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-283,200	Closed	-$1.71M	–	64
2019 Q4	$1.71M	Hold	283,200	–	–	0.6%	25
2019 Q3	$1.02M	Hold	283,200	–	–	0.64%	23
2019 Q2	$759K	Hold	283,200	–	–	0.27%	24
2019 Q1	$838K	Buy	+283,200	New	+$696K	0.16%	26

Kerrisdale Advisers's ACHN Position: Q1 2020 in Review

Kerrisdale Advisers sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 283,200 shares — an estimated $1.71M sold.

Kerrisdale Advisers first reported a position in ACHN in Q1 2019 and held it in 4 quarters. The position peaked at $1.71M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

Kerrisdale Advisers reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Kerrisdale Advisers sold 283,200 Achillion Pharmaceuticals shares in Q1 2020, an estimated $1.71M.
Kerrisdale Advisers first reported a position in Achillion Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Kerrisdale Advisers's Achillion Pharmaceuticals position peaked at $1.71M in Q4 2019.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Kerrisdale Advisers's 13F filing for Q1 2020, filed 15 May 2020.